Editas Medicine Inc.

40.39+0.8800+2.23%Vol 775.96K1Y Perf 80.27%
Apr 13th, 2021 14:21 DELAYED
BID40.36 ASK40.43
Open39.13 Previous Close39.51
Pre-Market39.48 After-Market-
 -0.03 -0.08%  - -
Target Price
50.83 
Analyst Rating
Moderate Buy 2.29
Potential %
26.00 
Finscreener Ranking
★★★     51.03
Insiders Trans % 3/6/12 mo.
-/-60/-78 
Value Ranking
★★★     50.85
Insiders Value % 3/6/12 mo.
75/-21/-38 
Growth Ranking
★★★+     55.32
Insiders Shares Cnt. % 3/6/12 mo.
83/-20/-41 
Income Ranking
 —    -
Market Cap2.72B 
Earnings Rating
Buy
Price Range Ratio 52W %
24.17 
Earnings Date
6th May 2021

Today's Price Range

39.1241.65

52W Range

21.4199.95

5 Year PE Ratio Range

-8.20-10.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.34%
1 Month
-14.63%
3 Months
-46.10%
6 Months
20.57%
1 Year
80.27%
3 Years
13.89%
5 Years
3.46%
10 Years
-

TickerPriceChg.Chg.%
EDIT40.390.88002.23
AAPL134.253.01002.29
GOOG2 263.598.80000.39
MSFT257.942.03000.79
XOM55.720.22000.40
WFC39.85-0.9200-2.26
JNJ158.91-2.7300-1.69
FB312.130.59000.19
GE13.46-0.1300-0.96
JPM154.56-1.3900-0.89
Financial StrengthValueIndustryS&P 500US Markets
7.00
7.20
0.05
0.07
49.90
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-118.50
-114.60
-721.10
-87.89
RevenueValueIndustryS&P 500US Markets
85.01M
1.26
58.20
90.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.82-1.00-21.95
Q03 2020-0.660.12118.18
Q02 2020-0.80-0.4346.25
Q01 2020-0.78-0.6911.54
Q04 20190.35-0.74-311.43
Q03 2019-0.73-0.669.59
Q02 2019-0.59-0.69-16.95
Q01 2019-0.57-0.60-5.26
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.769.52Positive
6/2021 QR-0.834.60Positive
12/2021 FY-3.49-3.25Negative
12/2022 FY-3.570.00-
Next Report Date6th May 2021
Estimated EPS Next Report-0.76
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume775.96K
Shares Outstanding67.36M
Trades Count12.99K
Dollar Volume168.10M
Avg. Volume2.47M
Avg. Weekly Volume985.51K
Avg. Monthly Volume1.50M
Avg. Quarterly Volume2.41M

Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 39.51 per share at the end of the most recent trading day (a 0.13% change compared to the prior day closing price) with a volume of 1.10M shares and market capitalization of 2.72B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.

The one-year performance of Editas Medicine Inc. stock is 80.27%, while year-to-date (YTD) performance is -43.65%. EDIT stock has a five-year performance of 3.46%. Its 52-week range is between 21.41 and 99.95, which gives EDIT stock a 52-week price range ratio of 24.17%

Editas Medicine Inc. currently has a PE ratio of -19.90, a price-to-book (PB) ratio of 6.98, a price-to-sale (PS) ratio of 31.31, a price to cashflow ratio of 616.40, a PEG ratio of 2.32, a ROA of -20.59%, a ROC of -26.24% and a ROE of -34.15%. The company’s profit margin is -87.89%, its EBITDA margin is -114.60%, and its revenue ttm is $85.01 Million , which makes it $1.26 revenue per share.

Of the last four earnings reports from Editas Medicine Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.76 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.29), with a target price of $50.83, which is +26.00% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Editas Medicine Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.00, ATR14 : 5.40, CCI20 : -100.67, Chaikin Money Flow : -0.08, MACD : -5.81, Money Flow Index : 23.40, ROC : -3.61, RSI : 38.65, STOCH (14,3) : 20.99, STOCH RSI : 1.00, UO : 33.56, Williams %R : -79.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Charles Albright (Option Excercise at a value of $990 600), Charles Albright (Sold 66 540 shares of value $2 816 949 ), Cynthia Collins (Sold 5 214 shares of value $228 993 ), James C. Mullen (Buy at a value of $1 156 800), Jessica Hopfield (Buy at a value of $263 970), Michelle Robertson (Sold 1 568 shares of value $122 727 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (28.57 %)
1 (16.67 %)
2 (28.57 %)
Moderate Buy
1 (14.29 %)
1 (16.67 %)
1 (14.29 %)
Hold
4 (57.14 %)
4 (66.67 %)
4 (57.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.29
Moderate Buy
2.50
Moderate Buy
2.29

Editas Medicine Inc.

Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.

CEO: Cynthia Collins

Telephone: +1 617 401-9000

Address: 11 Hurley Street, Cambridge 02141, MA, US

Number of employees: 235

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

News

Stocktwits